Catalog #SIM0048

InVivoSIM anti-human amyloid beta (Donanemab Biosimilar)

Clone Donanemab
Reactivities Human
Isotype Human IgG1, κ

$235.00 - $8,140.00

$235.00 - $8.00

Choose an Option...
  • 100 mg - $8,140.00
  • 50 mg - $4,574.00
  • 25 mg - $3,182.00
  • 5 mg - $911.00
  • 1 mg - $235.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Donanemab, making it ideal for research use. Donanemab is a humanized IgG1κ anti-human APP antibody, and it specifically reacts with abeta 42 (Aβ42), a pyroglutamate form of Aβ that is aggregated in amyloid plaques during the pathogenesis of Alzheimer’s disease (AD). Aβ42 results from an aberrant processing of amyloid-β protein precursor (APP or AβPP). The initial cleavage of APP is caused by either α- secretase or β-secretase (or BACE1). sAPPα and the α-C-terminal fragment (α-CTF or APP-C83) are produced by α-secretase cleavage of APP, whereas sAPPβ and the β-C-terminal fragment (β-CTF or APP-C99) are produced by β-secretase cleavage. γ-secretase further cleaves C83 and C99, yielding the P3 peptide and Aβ, respectively. Depending on the location of the γ-secretase cleavage, Aβ can have a length of 37-43 amino acids in its peptide sequence. The two main Aβ species are Aβ42 and Aβ40. In early AD pathology, Aβ species play a critical role by seeding toxic oligomeric species with Aβ42 being more preferentially depositing in amyloid plaques than Aβ40. Donanemab specifically recognizes Aβ p3-42 (Aβ42) and it is reported to impede the progression of AD by clearing plaques through microglial-mediated phagocytosis in mice without causing microhemorrhages. Donanemab biosimilar antibodies are commonly used for in vitro and in vivo studies involving Alzheimer's disease and Down syndrome experimental models.

Specifications

Isotype Human IgG1, κ
Recommended Isotype Control(s) RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen Human APP
Reported Applications in vivo functional assays
in vitro functional assays
ELISA
Western blot
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL gel clotting assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Product FAQs

Related Products

  1. Catalog #BE0368
    InVivoMAb anti-human/mouse/rat amyloid-beta Read more
  2. Catalog #SIM0032
    InVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar) Read more
  3. Catalog #SIM0047
    InVivoSIM anti-human amyloid-beta (Solanezumab Biosimilar) Read more